Skip to main content
Top
Published in: Cancer Cell International 1/2011

Open Access 01-12-2011 | Primary research

Effect of Benzothiazole based conjugates in causing apoptosis by Regulating p53, PTEN and MAP Kinase proteins affecting miR-195a and miR-101-1

Authors: SNCVL Pushpavalli, M Janaki Ramaiah, Ch Srinivas, Debasmita Mukhopadhya, JL Aditya, Ravindra M Kumbhare, Utpal Bhadra, Manika Pal Bhadra

Published in: Cancer Cell International | Issue 1/2011

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) accounts for majority of liver cancers and is the leading cause of cancer related death in Asia. Like any other cancer, HCC develops when there is a mutation to the cellular machinery that causes the cell to replicate at a higher rate and results in the loss of apoptosis. Therefore, a delicate balance between the expression of various genes involved in proliferation and apoptosis decide the ultimate fate of the cell to undergo rapid proliferation (cancer) or cell death.

Results

The benzothiazole based compounds exhibited effective cytotoxicity at 4 μM concentration and have shown G1 cell cycle arrest with decrease in levels of G1 cell cycle proteins such as cyclin D1 and Skp2. Involvement of tumour suppressor proteins such as PTEN and p53 was studied. Interestingly these compounds displayed decrease in the phosphorylated forms of AKT, p38 MAPK and ERK1/2 which play a vital role in cell proliferation. Compounds have exhibited strong and significant effect on the expression of micro RNAs such as miR-195a & miR-101-1 which regulate hepatic cell proliferation.

Conclusions

The cell cycle arrest and apoptotic inducing nature of these compounds was revealed by FACS, BrdU cell proliferation and tunel assays. Compounds affected both tumour suppressor proteins as well as proteins that are involved in active cell proliferation. Micro RNAs whose target is Cyclin D1 such as miR-195a and miR-101-1 that is required for growth of hepatoma cells was drastically affected. These compounds caused apoptosis by activating caspase-3 and PARP.
Appendix
Available only for authorised users
Literature
1.
go back to reference Farazi PA, Glickman J, Horner J, Depinho RA: Cooperative interactions of p53 mutation, telomere dysfunction and chronic liver damage in hepatocellular carcinoma progression. Cancer Res. 2006, 66 (9): 4766-73. 10.1158/0008-5472.CAN-05-4608.CrossRefPubMed Farazi PA, Glickman J, Horner J, Depinho RA: Cooperative interactions of p53 mutation, telomere dysfunction and chronic liver damage in hepatocellular carcinoma progression. Cancer Res. 2006, 66 (9): 4766-73. 10.1158/0008-5472.CAN-05-4608.CrossRefPubMed
2.
go back to reference Lo A, Lin CT, Wu HC: Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther. 2008, 7 (3): 579-89. 10.1158/1535-7163.MCT-07-2359.CrossRefPubMed Lo A, Lin CT, Wu HC: Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther. 2008, 7 (3): 579-89. 10.1158/1535-7163.MCT-07-2359.CrossRefPubMed
3.
go back to reference Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, Liang X, Lu CX: PTEN inhibits the migration and invasion of HepG2 cells by co-ordinately decreasing MMP expression via PI3K/AKT pathway. Oncol Rep. 2010, 23 (6): 1593-1600.PubMed Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, Liang X, Lu CX: PTEN inhibits the migration and invasion of HepG2 cells by co-ordinately decreasing MMP expression via PI3K/AKT pathway. Oncol Rep. 2010, 23 (6): 1593-1600.PubMed
4.
go back to reference Charette N, Saeger CD, Lannoy V, Horsmans Y, Leclerq I, Starkel P: Salirasib inhibits the growth of hepato carcinoma cell lines invitro and tumour growth invivo through ras and mTOR inhibition. Mol Cancer. 2010, 9: 256-10.1186/1476-4598-9-256.PubMedCentralCrossRefPubMed Charette N, Saeger CD, Lannoy V, Horsmans Y, Leclerq I, Starkel P: Salirasib inhibits the growth of hepato carcinoma cell lines invitro and tumour growth invivo through ras and mTOR inhibition. Mol Cancer. 2010, 9: 256-10.1186/1476-4598-9-256.PubMedCentralCrossRefPubMed
5.
go back to reference Carnero A: The PKB/AKT pathway in cancer. Curr Pharm Des. 2010, 16 (1): 34-44. 10.2174/138161210789941865.CrossRefPubMed Carnero A: The PKB/AKT pathway in cancer. Curr Pharm Des. 2010, 16 (1): 34-44. 10.2174/138161210789941865.CrossRefPubMed
6.
go back to reference Johnson GL, Lapadat R: Mitogen- activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science. 2002, 298 (5600): 1911-12. 10.1126/science.1072682.CrossRefPubMed Johnson GL, Lapadat R: Mitogen- activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science. 2002, 298 (5600): 1911-12. 10.1126/science.1072682.CrossRefPubMed
7.
go back to reference Zeng JZ, Wang HY, Chen ZJ, Ullrich A, Wu MC: Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma. Oncogene. 2002, 21: 4932-4943. 10.1038/sj.onc.1205652.CrossRefPubMed Zeng JZ, Wang HY, Chen ZJ, Ullrich A, Wu MC: Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma. Oncogene. 2002, 21: 4932-4943. 10.1038/sj.onc.1205652.CrossRefPubMed
8.
go back to reference Yamada KM, Araki M: Tumour suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J cell Sci. 2001, 114: 2375-2382.PubMed Yamada KM, Araki M: Tumour suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J cell Sci. 2001, 114: 2375-2382.PubMed
9.
go back to reference Strasser A, O'Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem. 2000, 69: 217-245. 10.1146/annurev.biochem.69.1.217.CrossRefPubMed Strasser A, O'Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem. 2000, 69: 217-245. 10.1146/annurev.biochem.69.1.217.CrossRefPubMed
10.
go back to reference Ikeguchi M, Hirooka Y, Kaibara N: Quantitative analysis of apoptosis-related gene expression in hepato cellular carcinoma. Cancer. 2002, 95 (9): 1938-1945. 10.1002/cncr.10898.CrossRefPubMed Ikeguchi M, Hirooka Y, Kaibara N: Quantitative analysis of apoptosis-related gene expression in hepato cellular carcinoma. Cancer. 2002, 95 (9): 1938-1945. 10.1002/cncr.10898.CrossRefPubMed
11.
go back to reference Lynam-Lennon N, Maher SG, Reynolds JV: The roles of micro RNA in cancer and apoptosis. Biol Rev Camb Philos Soc. 2009, 84 (1): 55-71. 10.1111/j.1469-185X.2008.00061.x.CrossRefPubMed Lynam-Lennon N, Maher SG, Reynolds JV: The roles of micro RNA in cancer and apoptosis. Biol Rev Camb Philos Soc. 2009, 84 (1): 55-71. 10.1111/j.1469-185X.2008.00061.x.CrossRefPubMed
12.
go back to reference Hummel R, Hussey DJ, Haier J: Micro RNAs: predictors and modifiersof chemo- and radiotherapy in different tumour types. Eur J cancer. 2010, 46 (2): 298-311. 10.1016/j.ejca.2009.10.027.CrossRefPubMed Hummel R, Hussey DJ, Haier J: Micro RNAs: predictors and modifiersof chemo- and radiotherapy in different tumour types. Eur J cancer. 2010, 46 (2): 298-311. 10.1016/j.ejca.2009.10.027.CrossRefPubMed
13.
go back to reference Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhung SM: Micro RNA-195 suppresses tumourigenicity and regulates G1/S transition of human hepato cellular carcinoma cells. Hepatology. 2009, 50 (1): 113-21. 10.1002/hep.22919.CrossRefPubMed Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhung SM: Micro RNA-195 suppresses tumourigenicity and regulates G1/S transition of human hepato cellular carcinoma cells. Hepatology. 2009, 50 (1): 113-21. 10.1002/hep.22919.CrossRefPubMed
14.
go back to reference Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: Micro RNA- 101, down regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumourigenicity. Cancer Res. 2009, 69 (3): 1135-1142. 10.1158/0008-5472.CAN-08-2886.CrossRefPubMed Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: Micro RNA- 101, down regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumourigenicity. Cancer Res. 2009, 69 (3): 1135-1142. 10.1158/0008-5472.CAN-08-2886.CrossRefPubMed
15.
go back to reference Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Matsuhisa A, Kudoh M, Shibasaki M: YM-201627: An orally active antitumour agent with selective inhibition of vascular endothelial cell proliferation. Cancer Lett. 2006, 238: 119-127. 10.1016/j.canlet.2005.06.037.CrossRefPubMed Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Matsuhisa A, Kudoh M, Shibasaki M: YM-201627: An orally active antitumour agent with selective inhibition of vascular endothelial cell proliferation. Cancer Lett. 2006, 238: 119-127. 10.1016/j.canlet.2005.06.037.CrossRefPubMed
16.
go back to reference Cardones AR, Banez LL: VEGF inhibitors in cancer therapy. Curr Pharm Design. 2006, 12 (3): 387-394. 10.2174/138161206775201910.CrossRef Cardones AR, Banez LL: VEGF inhibitors in cancer therapy. Curr Pharm Design. 2006, 12 (3): 387-394. 10.2174/138161206775201910.CrossRef
17.
go back to reference Davies MA, Lu Y, Sano T, Fang X, Tang P, Lapushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA: Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998, 58: 5285-5290.PubMed Davies MA, Lu Y, Sano T, Fang X, Tang P, Lapushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA: Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998, 58: 5285-5290.PubMed
18.
go back to reference Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS: Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007, 117 (9): 2713-2722. 10.1172/JCI31457.PubMedCentralCrossRefPubMed Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS: Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007, 117 (9): 2713-2722. 10.1172/JCI31457.PubMedCentralCrossRefPubMed
19.
go back to reference Fan J, Bertino JR: K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene. 1997, 14: 2595-2607. 10.1038/sj.onc.1201105.CrossRefPubMed Fan J, Bertino JR: K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene. 1997, 14: 2595-2607. 10.1038/sj.onc.1201105.CrossRefPubMed
20.
go back to reference Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH-3T3 cells. Cell. 1994, 77 (6): 841-852. 10.1016/0092-8674(94)90133-3.CrossRefPubMed Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH-3T3 cells. Cell. 1994, 77 (6): 841-852. 10.1016/0092-8674(94)90133-3.CrossRefPubMed
21.
go back to reference Sale EM, Atkinson PG, Sale GJ: Requirement of MAPKinase for differentiation of fibroblasts to adipocytes, for insulin activation of p90 S6 kinase and for insulin or serum stimulation of DNA synthesis. EMBO J. 1995, 14 (4): 674-684.PubMedCentralPubMed Sale EM, Atkinson PG, Sale GJ: Requirement of MAPKinase for differentiation of fibroblasts to adipocytes, for insulin activation of p90 S6 kinase and for insulin or serum stimulation of DNA synthesis. EMBO J. 1995, 14 (4): 674-684.PubMedCentralPubMed
22.
go back to reference Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP Kinase pathway. Oncogene. 2000, 19 (56): 6594-9. 10.1038/sj.onc.1204083.CrossRefPubMed Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP Kinase pathway. Oncogene. 2000, 19 (56): 6594-9. 10.1038/sj.onc.1204083.CrossRefPubMed
23.
go back to reference Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean central cancer registry program 2000: Based on registered data from 131 hospitals. Cancer Res Treat. 2002, 34 (2): 77-83. Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean central cancer registry program 2000: Based on registered data from 131 hospitals. Cancer Res Treat. 2002, 34 (2): 77-83.
24.
go back to reference Debatin KM: Activation of apoptosis pathways by anti-cancer drugs. Adv Exp Med Biol. 1999, 457: 237-244. 10.1007/978-1-4615-4811-9_25.CrossRefPubMed Debatin KM: Activation of apoptosis pathways by anti-cancer drugs. Adv Exp Med Biol. 1999, 457: 237-244. 10.1007/978-1-4615-4811-9_25.CrossRefPubMed
25.
go back to reference Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB: Amplification and over expression of Cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993, 196 (2): 1010-1016. 10.1006/bbrc.1993.2350.CrossRefPubMed Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB: Amplification and over expression of Cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993, 196 (2): 1010-1016. 10.1006/bbrc.1993.2350.CrossRefPubMed
26.
go back to reference Stambolic V, Mac Pherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW: Regulation of PTEN transcription by p53. Mol Cell. 2001, 8 (2): 317-325. 10.1016/S1097-2765(01)00323-9.CrossRefPubMed Stambolic V, Mac Pherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW: Regulation of PTEN transcription by p53. Mol Cell. 2001, 8 (2): 317-325. 10.1016/S1097-2765(01)00323-9.CrossRefPubMed
27.
go back to reference Furnari FB, Lin H, Huang HS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA. 1997, 94: 2479-12484.CrossRef Furnari FB, Lin H, Huang HS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA. 1997, 94: 2479-12484.CrossRef
28.
go back to reference Mayo LD, Donner DB: A phosphatidyl inositol 3- kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 2001, 98 (20): 11598-11603. 10.1073/pnas.181181198.PubMedCentralCrossRefPubMed Mayo LD, Donner DB: A phosphatidyl inositol 3- kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 2001, 98 (20): 11598-11603. 10.1073/pnas.181181198.PubMedCentralCrossRefPubMed
29.
go back to reference Zhang B, Pan X, Cobb GP, Anderson TA: Micro RNAs as oncogenes and tumour suppressors. Dev Biol. 2007, 302 (1): 1-12. 10.1016/j.ydbio.2006.08.028.CrossRefPubMed Zhang B, Pan X, Cobb GP, Anderson TA: Micro RNAs as oncogenes and tumour suppressors. Dev Biol. 2007, 302 (1): 1-12. 10.1016/j.ydbio.2006.08.028.CrossRefPubMed
30.
go back to reference Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: Micro RNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-8. 10.1038/nature03702.CrossRefPubMed Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: Micro RNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-8. 10.1038/nature03702.CrossRefPubMed
31.
go back to reference Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A micro RNA expression signature of human solid tumours defines cancer gene targets. Proc Natl Acad Sci USA. 2006, 103 (7): 2257-61. 10.1073/pnas.0510565103.PubMedCentralCrossRefPubMed Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A micro RNA expression signature of human solid tumours defines cancer gene targets. Proc Natl Acad Sci USA. 2006, 103 (7): 2257-61. 10.1073/pnas.0510565103.PubMedCentralCrossRefPubMed
33.
go back to reference Lakhani SA, Masud A, Kuida K, Porter GA, Booth CJ, Mehal WZ, Inayat I, Flavell RA: Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis. Science. 2006, 311 (5762): 847-851. 10.1126/science.1115035.PubMedCentralCrossRefPubMed Lakhani SA, Masud A, Kuida K, Porter GA, Booth CJ, Mehal WZ, Inayat I, Flavell RA: Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis. Science. 2006, 311 (5762): 847-851. 10.1126/science.1115035.PubMedCentralCrossRefPubMed
34.
go back to reference Sethi G, Sung B, Aggarwal BB: Flavopiridol suppresses tumour necrosis factor induced activation of activator protein-1, C-Jun N-terminal kinase, p38 mitogen activated protein kinase (MAPK), p44/p42 MAPK and Akt, inhibits expression of antiapoptotic gene products and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Molecular Pharmacol. 2008, 73: 1549-1557. 10.1124/mol.107.041350.CrossRef Sethi G, Sung B, Aggarwal BB: Flavopiridol suppresses tumour necrosis factor induced activation of activator protein-1, C-Jun N-terminal kinase, p38 mitogen activated protein kinase (MAPK), p44/p42 MAPK and Akt, inhibits expression of antiapoptotic gene products and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Molecular Pharmacol. 2008, 73: 1549-1557. 10.1124/mol.107.041350.CrossRef
Metadata
Title
Effect of Benzothiazole based conjugates in causing apoptosis by Regulating p53, PTEN and MAP Kinase proteins affecting miR-195a and miR-101-1
Authors
SNCVL Pushpavalli
M Janaki Ramaiah
Ch Srinivas
Debasmita Mukhopadhya
JL Aditya
Ravindra M Kumbhare
Utpal Bhadra
Manika Pal Bhadra
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2011
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-11-36

Other articles of this Issue 1/2011

Cancer Cell International 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine